{"id":"epoetin-alfa-40000-unt-ml","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Hypertension"},{"rate":"5-15%","effect":"Thrombosis/thromboembolic events"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL1201565","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a glycoprotein that mimics endogenous erythropoietin, promoting erythropoiesis through activation of the erythropoietin receptor on erythroid progenitor and precursor cells in the bone marrow. This leads to increased hemoglobin and hematocrit levels. It is used to treat anemia associated with chronic kidney disease, chemotherapy, and other conditions.","oneSentence":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:16.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia of chronic kidney disease"},{"name":"Chemotherapy-induced anemia"},{"name":"Anemia in critical illness (Phase 3 investigational)"}]},"trialDetails":[{"nctId":"NCT04588311","phase":"PHASE3","title":"ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients","status":"RECRUITING","sponsor":"Australian and New Zealand Intensive Care Research Centre","startDate":"2020-11-09","conditions":"Trauma, Traumatic Injury, Traumatic Brain Injury","enrollment":2500},{"nctId":"NCT03822884","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Bio Sidus SA","startDate":"2016-09","conditions":"Anemia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eprex","Binocrit","Hemax","Hemax PFS","Erypo"],"phase":"phase_3","status":"active","brandName":"Epoetin Alfa 40000 UNT/ML","genericName":"Epoetin Alfa 40000 UNT/ML","companyName":"Australian and New Zealand Intensive Care Research Centre","companyId":"australian-and-new-zealand-intensive-care-research-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Anemia in critical illness (Phase 3 investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}